Phase 1a/b Study for Selective Brain-Penetrant CDK2 Inhibitor AL-605 doses patients; Selective Brain-Penetrant CDK4 Inhibitor AL-433 on Track for First-in-Human Study SAN DIEGO, May 29, 2026 ...

AbbVie’s ultra-rare blood cancer ADC secured FDA clearance while AstraZeneca’s oral SERD for breast cancer remains in regulatory limbo.

Avenzo Therapeutics Announces First Patient Dosed in Combination Cohort Evaluating AVZO-023 (CDK4i) with AVZO-021 (CDK2i) In Phase 1/2 ORION-1 Study ...

US FDA extends PDUFA date and seeks additional data from AstraZeneca’s NDA for camizestrant in combo with a CDK 4/6 inhibitor to treat HR-positive, HER2-negative advanced breast ...

AstraZeneca (AZN) stock is in focus as the FDA delays review of a breast cancer therapy containing its next-gen oral SERD ...

EU Committee recommends approval of AstraZeneca’s camizestrant for 1st-line advanced ER-positive breast cancer: Cambridge, UK Monday, May 25, 2026, 09:00 Hrs [IST] AstraZenecas ...

AstraZeneca PLC on Friday announced one approval and two recommendations for three products, for different cancer indications, in the US and EU. The Cambridge-based pharmaceutical company's drug ...

AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) has been ...

AstraZeneca advances its ambition to eliminate cancer as a cause of death and transform outcomes for people living with rare diseases with new data ...

Pfizer has reported positive results from its Phase II trial evaluating the 25-valent pneumococcal conjugate vaccine candidate, PF-07872412, in infants.

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), will present new data from nine approved and investigational medicines across more than 15 indications at the 2026 American Society ...